Study on DMD06-MAB Injection for Duchenne Muscular Dystrophy in Non-Ambulant Patients

2 1 1

What is this study about?

This clinical trial is focused on studying Duchenne Muscular Dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness. The treatment being tested is called DMD06-MAB, which involves a single injection of specially prepared cells known as mesoangioblasts (MABs) into specific muscles. These cells are genetically modified to help correct a part of the dystrophin gene, which is responsible for muscle function. The aim of the study is to evaluate the safety of this treatment and its ability to restore the production of dystrophin, a protein that is lacking in individuals with DMD.

The study will involve five participants who are unable to walk due to DMD. Each participant will receive an injection of the genetically corrected MABs into a muscle in the foot. The researchers will monitor the participants for any adverse effects and will also check if the treatment successfully increases the levels of dystrophin in the muscle. The study will last for one year, during which the safety and effectiveness of the treatment will be closely observed.

Participants will be monitored for any local or systemic adverse events following the injection. The primary goal is to ensure the treatment is safe and to determine if there is an increase in dystrophin levels in the muscle, which will be assessed through muscle biopsies. The study is designed to provide valuable information on the potential of this innovative treatment for improving muscle function in individuals with Duchenne Muscular Dystrophy.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes verifying age, non-ambulant status, and a confirmed diagnosis of Duchenne Muscular Dystrophy with specific genetic mutations.

A quantitative MRI is performed to assess muscle degeneration, ensuring it is within the required range.

2 informed consent

Written informed consent is obtained from caregivers, and the patient’s assent is required to proceed with the study.

3 pre-injection preparation

Pre-clinical safety assessments are conducted on the treatment product, DMD06-MAB, to ensure it is safe for use.

4 treatment administration

A single injection of DMD06-MAB, a suspension for injection, is administered intramuscularly into the foot muscle known as the Extensor Digitorum Brevis (EDB).

The treatment involves genetically corrected cells designed to help restore dystrophin production in the muscle.

5 post-injection monitoring

Monitoring for adverse events occurs over the course of one year following the injection. This includes both local reactions at the injection site and any systemic effects.

Regular assessments are conducted to evaluate the presence of dystrophin in the muscle, aiming for levels comparable to at least 10% of a healthy individual.

6 efficacy evaluation

Three months after the injection, a muscle biopsy is performed to assess the presence of dystrophin using various laboratory techniques.

The goal is to confirm the effectiveness of the treatment in restoring dystrophin production in the treated muscle.

Who Can Join the Study?

Must be a boy aged between 12 and 17 years old at the time of joining the study.
Cannot walk at the time of joining the study.
Must have a confirmed diagnosis of Duchenne Muscular Dystrophy (DMD) with specific changes in the dystrophin gene that can be treated by skipping exon 51. The dystrophin gene is important for muscle function.
Muscle loss should not be more than 50%, as measured by a special scan called quantitative MRI. This scan helps to see how much muscle is left.
Caregivers must provide written permission for the patient to join the study, and the patient must agree to participate.

Who Cannot Join the Study?

Patients who do not have Duchenne Muscular Dystrophy cannot participate. This is a genetic disorder that affects muscles.
Females cannot participate in this study. Only males are eligible.
Patients who are not within the specified age range for the study cannot participate. The exact age range is not provided here.
Patients who are part of a vulnerable population, which means they might need special protection or care, cannot participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Ospedale San Raffaele S.r.l.	Milan	Italy

Trial status

Country	Status	Recruitment Start
Italy	Not recruiting	27.06.2024

Trial locations

Autologous Mesoangioblasts (MABs): These are special cells taken from the patient’s own body. In this trial, they are genetically corrected to help produce dystrophin, a protein that is missing or not working properly in patients with Duchenne Muscular Dystrophy. The corrected cells are injected into specific muscles to see if they can help restore the production of dystrophin and improve muscle function.

Investigated diseases:

Duchenne muscular dystrophy

Duchenne Muscular Dystrophy – Duchenne Muscular Dystrophy is a genetic disorder characterized by progressive muscle weakness and degeneration. It primarily affects boys and is caused by mutations in the dystrophin gene, which is crucial for maintaining muscle cell structure. Symptoms usually begin in early childhood, with affected individuals experiencing difficulty in walking, running, and jumping. As the disease progresses, muscle weakness spreads to the arms, neck, and other areas, leading to increased difficulty in performing daily activities. Over time, individuals may lose the ability to walk and require the use of a wheelchair. The progression of muscle weakness can also affect the heart and respiratory muscles.

Trial ID:

2024-514860-14-00

Trial Phase:

Phase I and Phase II (Integrated) – First administration to humans

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on DMD06-MAB Injection for Duchenne Muscular Dystrophy in Non-Ambulant Patients

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?